Literature DB >> 34287768

Steroid Phobia: A Review of Prevalence, Risk Factors, and Interventions.

Marissa Contento1, Abigail Cline2, Marian Russo2.   

Abstract

Topical corticosteroid phobia may lead to poor adherence, resulting in persistent disease and escalation to systemic agents. The aim of this paper was to review current literature to assess topical steroid phobia prevalence, populations most at risk, reasons behind steroid phobia, and interventions to reduce it. A systematic search of PubMed, Ovid (Journals@Ovid, MEDLINE), ScienceDirect, and Web of Science was performed. Studies ranged from May 2000 to February 2021. In total, 37 articles met the inclusion criteria. There was inter-study variation in the way steroid phobia is defined, from concern to irrational fear. The worldwide prevalence of topical steroid phobia ranges from 31 to 95.7% and does not differ with patient race/ethnicity or dermatological condition. Female patients and caregivers, and those who have experienced side effects of topical corticosteroids are most likely to express steroid phobia. Reasons for steroid phobia include lack of education, fear of side effects, polypharmacy, misinformation, negative experience with topical steroids, and frequently changing of clinics. Successful interventions to address steroid phobia include patient education in the form of educational videos followed by individualized oral education based on concerns, and demonstrations of application of topical steroids. Multiple interventions address topical corticosteroid phobia and improve adherence of topical corticosteroids in the management of dermatological conditions. Providers should screen patients for steroid phobia, especially in populations particularly at risk. Interventions using patient education should be individualized based on concerns expressed during screening. Further research should investigate if reducing steroid phobia can in fact improve long-term adherence.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34287768     DOI: 10.1007/s40257-021-00623-6

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  39 in total

1.  Assessment of "corticophobia" as an indicator of non-adherence to topical corticosteroids: A pilot study.

Authors:  Simon M Mueller; Peter Itin; Deborah R Vogt; Marc Walter; Undine Lang; Liezel L Griffin; Sebastian Euler
Journal:  J Dermatolog Treat       Date:  2016-07-10       Impact factor: 3.359

2.  Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis.

Authors:  Jennifer Krejci-Manwaring; Mark G Tusa; Christie Carroll; Fabian Camacho; Mandeep Kaur; David Carr; Alan B Fleischer; Rajesh Balkrishnan; Steven R Feldman
Journal:  J Am Acad Dermatol       Date:  2006-11-13       Impact factor: 11.527

3.  Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency.

Authors:  H Aubert-Wastiaux; L Moret; A Le Rhun; A M Fontenoy; J M Nguyen; C Leux; L Misery; P Young; M Chastaing; N Danou; P Lombrail; F Boralevi; J P Lacour; J Mazereeuw-Hautier; J-F Stalder; S Barbarot
Journal:  Br J Dermatol       Date:  2011-09-15       Impact factor: 9.302

4.  Topical corticosteroid phobia in patients with atopic eczema.

Authors:  C R Charman; A D Morris; H C Williams
Journal:  Br J Dermatol       Date:  2000-05       Impact factor: 9.302

5.  Steroid fears in children with eczema.

Authors:  Kam-Lun Ellis Hon; Wai-Yan Christy Kam; Ting-Fan Leung; Man-Ching Adrian Lam; Kin-Yee Wong; Kwing-Chin Kenneth Lee; Nai-Ming Tommy Luk; Tai-Fai Fok; Pak-Cheung Ng
Journal:  Acta Paediatr       Date:  2006-11       Impact factor: 2.299

6.  Topical Corticosteroid Concerns in Dermatological Outpatients: A Cross-Sectional and Interventional Study.

Authors:  Simon M Müller; Dominique Tomaschett; Sebastian Euler; Deborah R Vogt; Lisa Herzog; Peter Itin
Journal:  Dermatology       Date:  2016-06-21       Impact factor: 5.366

7.  Treatment of Atopic Dermatitis in the United States: Analysis of Data from the National Ambulatory Medical Care Survey.

Authors:  Sean P McGregor; Michael E Farhangian; Karen E Huang; Steven R Feldman
Journal:  J Drugs Dermatol       Date:  2017-03-01       Impact factor: 2.114

Review 8.  Topical Corticosteroid Phobia in Atopic Dermatitis: A Systematic Review.

Authors:  Alvin W Li; Emily S Yin; Richard J Antaya
Journal:  JAMA Dermatol       Date:  2017-10-01       Impact factor: 10.282

9.  Monitoring of topical corticosteroid phobia in a population of parents with children with atopic dermatitis using the TOPICOP® scale: prevalence, risk factors and the impact of therapeutic patient education.

Authors:  F Gonzales; N Ramdane; C Delebarre-Sauvage; P Modiano; A Duhamel; A Lasek
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-09-30       Impact factor: 6.166

10.  Corticosteroid phobia: a questionnaire study using TOPICOP score.

Authors:  Ellie Choi; Nisha Suyien Chandran; Chris Tan
Journal:  Singapore Med J       Date:  2019-09-19       Impact factor: 1.858

View more
  2 in total

Review 1.  Platelet-Rich Plasma in Alopecia Areata-A Steroid-Free Treatment Modality: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Authors:  Fanni Adél Meznerics; Kata Illés; Fanni Dembrovszky; Péter Fehérvári; Lajos Vince Kemény; Kata Dorottya Kovács; Norbert Miklós Wikonkál; Dezső Csupor; Péter Hegyi; András Bánvölgyi
Journal:  Biomedicines       Date:  2022-07-29

2.  Naturopathic patient care during different life stages: an international observational study of naturopathic practitioners and their patients.

Authors:  Amie Steel
Journal:  BMC Health Serv Res       Date:  2022-07-26       Impact factor: 2.908

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.